Vertex signs agreement to acquire Crinetics for $10bn

Vertex has signed a definitive statement to acquisition Crinetics Pharmaceuticals successful a transaction valued astatine astir $10bn, oregon $8.8bn nett of estimated currency acquired.

Approved unanimously by some companies' boards, the acquisition volition spot Vertex wage $85.00 per stock successful currency for each outstanding shares of Crinetics.

It is expected to adjacent successful the 3rd 4th (Q3) of 2026, pending regulatory approvals and shareholder consent from Crinetics.

The transaction adds 2 main endocrinology assets to Vertex's portfolio.

Crinetics' Palsonify (paltusotine), a once-daily oral therapy for adults with acromegaly, was approved by the US Food and Drug Administration (FDA) successful September 2025 and besides by the European Medicines Agency (EMA) successful April 2026.

Acromegaly is simply a uncommon information usually caused by a pituitary tumour that leads to excess maturation hormone secretion.

The company's pipeline besides includes atumelnant, a once-daily oral adrenocorticotropic hormone receptor antagonist successful Phase III improvement for congenital adrenal hyperplasia (CAH).

CAH is simply a chronic familial upset characterised by impaired cortisol synthesis and excess androgen production.

Vertex has stated that the acquisition is anticipated to lend to its gross maturation from the ongoing motorboat of Palsonify, and that atumelnant, if approved, could besides make important gross successful CAH and perchance successful Cushing's syndrome.

The 2 assets unneurotic are projected by the companies to person a combined yearly highest income imaginable exceeding $5bn.

Vertex intends to money the acquisition with a substance of currency connected manus and debt, supported by a afloat committed span financing of $4.5bn from Bank of America and Morgan Stanley Senior Funding.

Vertex CEO and president Reshma Kewalramani said: "Crinetics is an fantabulous strategical acceptable for Vertex, with its absorption connected superior diseases successful speciality markets with important unmet need, well-understood causal quality biology, and perchance best-in-class medicines that could present transformative payment to patients.

"We are besides excited by the important imaginable of atumelnant to alteration the attraction scenery for CAH, mounting a caller modular of attraction wherever patients bash not person to take betwixt managing their excess adrenal androgens and enduring the broadside effects of high-dose steroids."

In April 2026, Halozyme Therapeutics' subsidiary Halozyme Hypercon signed a planetary exclusive concern and licence statement with Vertex for the Hypercon technology.

"Vertex signs statement to get Crinetics for $10bn" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.